Literature DB >> 8562477

Expression of the RET oncogene induces differentiation of SK-N-BE neuroblastoma cells.

A D'Alessio1, G De Vita, G Calì, L Nitsch, A Fusco, G Vecchio, G Santelli, M Santoro, V de Franciscis.   

Abstract

Expression of the RET proto-oncogene, a cell surface receptor for an as yet unknown ligand, is associated with tumors, tissues, and cell lines of neural crest origin. Accumulating evidence suggests that RET activity is involved in the process of neuronal differentiation. Moreover, induction of phenotypic differentiation of neuroblastoma cell lines is associated with the rapid accumulation of RET transcripts. To verify the role of RET in neuronal differentiation, we introduced into the human neuroblastoma cell line SK-N-BE four versions of the RET oncogene, activated by different mechanisms: RET/PTC1 and RET/PTC3, which are activated by rearrangement with heterologous genes; and two activated RET mutants, which carry the single amino acid substitution found associated to the inheritance of the multiple endocrine neoplasia type 2A (retMEN2A allele) and type2B (retMEN2B allele), respectively. We demonstrate that, after transfection with the RET oncogenes, SK-N-BE cells display a reduced growth rate and acquire a neurite-bearing phenotype accompanied by enhanced expression of the axonal growth-associated protein, GAP-43, and the high molecular weight neurofilament, NF200. These results indicate that, when activated, RET is able to cause growth inhibition and to promote neuronal differentiation of neuroblastoma cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8562477

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  7 in total

1.  Molecular heterogeneity of RET loss of function in Hirschsprung's disease.

Authors:  F Carlomagno; G De Vita; M T Berlingieri; V de Franciscis; R M Melillo; V Colantuoni; M H Kraus; P P Di Fiore; A Fusco; M Santoro
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

2.  Forced expression of NR4A3 induced the differentiation of human neuroblastoma-derived NB1 cells.

Authors:  Takayuki Hirano; Eri Nagasaki-Maeoka; Yoshiaki Ishizuka; Atsushi Takatori; Yosuke Watanabe; Reina Hoshi; Shinsuke Yoshizawa; Hiroyuki Kawashima; Shota Uekusa; Kiminobu Sugito; Shuichiro Uehara; Noboru Fukuda; Hiroki Nagase; Tadateru Takayama; Masayoshi Soma; Tsugumichi Koshinaga; Kyoko Fujiwara
Journal:  Med Oncol       Date:  2019-06-10       Impact factor: 3.064

3.  Enhancement of ATRA-induced differentiation of neuroblastoma cells with LOX/COX inhibitors: an expression profiling study.

Authors:  Petr Chlapek; Martina Redova; Karel Zitterbart; Marketa Hermanova; Jaroslav Sterba; Renata Veselska
Journal:  J Exp Clin Cancer Res       Date:  2010-05-11

Review 4.  Multiple endocrine neoplasias type 2B and RET proto-oncogene.

Authors:  Giuseppe Martucciello; Margherita Lerone; Lara Bricco; Gian Paolo Tonini; Laura Lombardi; Carmine G Del Rossi; Sergio Bernasconi
Journal:  Ital J Pediatr       Date:  2012-03-19       Impact factor: 2.638

5.  HLXB9 gene expression, and nuclear location during in vitro neuronal differentiation in the SK-N-BE neuroblastoma cell line.

Authors:  Claudia Giovanna Leotta; Concetta Federico; Maria Violetta Brundo; Sabrina Tosi; Salvatore Saccone
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

6.  Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo.

Authors:  Zhenghu Chen; Yanling Zhao; Yang Yu; Jonathan C Pang; Sarah E Woodfield; Ling Tao; Shan Guan; Huiyuan Zhang; Shayahati Bieerkehazhi; Yan Shi; Roma Patel; Sanjeev A Vasudevan; Joanna S Yi; Jodi A Muscal; Guo-Tong Xu; Jianhua Yang
Journal:  Oncotarget       Date:  2017-10-24

Review 7.  Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology.

Authors:  Esteban Javier Rozen; Jason Matthew Shohet
Journal:  Cancer Metastasis Rev       Date:  2021-10-30       Impact factor: 9.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.